Minako Koga

Title: Minako Koga: Innovator in Cell Therapy for Neurodegeneration

Introduction

Minako Koga is a prominent inventor based in Rockville, MD (US). She has made significant contributions to the field of cell therapy, particularly in the treatment of neurodegeneration. With a total of 3 patents to her name, Koga is at the forefront of innovative medical research.

Latest Patents

One of her latest patents focuses on cell therapy for the treatment of neurodegeneration. The methods described involve the isolation and selection of a heterogeneous bone marrow cell population, known as NCS-01, which has shown effectiveness in treating neurodegeneration caused by ischemia. In vivo studies have demonstrated that selected NCS-01 cell populations can treat neurodegeneration in a standard rat middle cerebral artery occlusion (MCAO) animal model, whether under conditions of transient or permanent total arterial occlusion. Furthermore, when neurodegeneration is caused by ischemic stroke, combining the administration of NCS-01 cells with thrombolytic agents and/or mechanical methods of clot removal has been shown to decrease the volume of infarction caused by acute onset neurodegeneration. This promising cell therapy has the potential to significantly impact patient survival rates after stroke.

Career Highlights

Minako Koga is currently associated with Nc Medical Research Inc., where she continues her groundbreaking work in medical research and innovation. Her dedication to advancing cell therapy has positioned her as a key figure in the field.

Collaborations

Some of her notable coworkers include Thomas N Chase and Keishin Sasaki, who contribute to her research endeavors and collaborative projects.

Conclusion

Minako Koga's innovative work in cell therapy for neurodegeneration exemplifies the potential of medical research to improve patient outcomes. Her contributions are paving the way for future advancements in the treatment of neurological conditions.